Rapport CEO sells 8,210 shares near $46
Rapport Therapeutics, Inc. (RAPP) reports that Chief Executive Officer and director Abraham Ceesay sold common stock in two open-market transactions on September 8, 2026 under pre-arranged Rule 10b5-1 trading plans adopted on March 27, 2026.
Rhea-AI Filing Summary
Rapport Therapeutics, Inc. (RAPP) reports that Chief Executive Officer and director Abraham Ceesay sold common stock in two open-market transactions on September 8, 2026 under pre-arranged Rule 10b5-1 trading plans adopted on March 27, 2026. He sold 7,141 shares at a weighted average price of $45.56 and 1,069 shares at a weighted average price of $46.01, for total reported sales of 8,210 shares. Following these transactions, indirect holdings in Rapport Therapeutics common stock include 81,729 shares held by the Ceesay Family Irrevocable Trust and 20,729 shares held by the Dorothy Ceesay Irrevocable Trust.
Positive
- None.
Negative
- None.
Insights
Analyzing...
Insider Trade Summary 10b5-1
Net Seller: 8,210 shares
Net Sell
4 txns
Insider
Ceesay Abraham
Role
Chief Executive Officer
Sold
8,210 shs ($374K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1, F2 | 7,141 | $45.555 | $325K |
| Sale | Common Stock F1, F3 | 1,069 | $46.0147 | $49K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 458,977 shares (Direct);
Common Stock — 81,729 shares (Indirect, By Ceesay Family Irrevocable Trust);
Common Stock — 20,729 shares (Indirect, By Dorothy Ceesay Irrevocable Trust)
Footnotes (3)
- F1. These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026.
- F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $44.94 to $45.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- F3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.95 to $46.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
Key Figures
Shares sold (larger transaction): 7,141 shares
Weighted average sale price (larger transaction): $45.56 per share
Price range (larger transaction): $44.94–$45.90 per share
+6 more
9 metrics
Shares sold (larger transaction)
7,141 shares
Common stock sold on September 8, 2026 in an open-market transaction
Weighted average sale price (larger transaction)
$45.56 per share
Common stock sale of 7,141 shares on September 8, 2026
Price range (larger transaction)
$44.94–$45.90 per share
Individual trades for the 7,141-share sale on September 8, 2026
Shares sold (smaller transaction)
1,069 shares
Common stock sold on September 8, 2026 in a second transaction
Weighted average sale price (smaller transaction)
$46.01 per share
Common stock sale of 1,069 shares on September 8, 2026
Price range (smaller transaction)
$45.95–$46.17 per share
Individual trades for the 1,069-share sale on September 8, 2026
Total shares sold
8,210 shares
Net shares sold across both reported transactions on September 8, 2026
Indirect trust holdings (Ceesay Family Irrevocable Trust)
81,729 shares
Common stock held indirectly after the reported transactions
Indirect trust holdings (Dorothy Ceesay Irrevocable Trust)
20,729 shares
Common stock held indirectly after the reported transactions
Key Terms
Rule 10b5-1 trading plans, weighted average price, irrevocable trust
3 terms
Rule 10b5-1 trading plans regulatory
"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026"
Rule 10b5-1 trading plans are written, pre-arranged instructions that allow company insiders (such as executives or directors) to automatically buy or sell their company's stock at specified times or under set conditions, like a standing instruction or automated thermostat for trades. They matter to investors because these plans provide a legal defense against insider‑trading accusations and create predictable insider trading patterns that can help signal whether sales are routine portfolio management or potentially meaningful to the company’s outlook.
weighted average price financial
"The price reported in Column 4 is a weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
irrevocable trust financial
"By Ceesay Family Irrevocable Trust"
An irrevocable trust is a legal arrangement where an owner transfers assets into a separate entity managed by a trustee and gives up the power to modify or reclaim those assets. For investors it matters because putting stock or other holdings into such a trust can change who controls and benefits from the assets, affect taxes and creditor protection, and influence how easy it is to sell or value those holdings—like placing valuables in a locked safe overseen by someone else.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider stock transactions did RAPP report for Abraham Ceesay on September 8, 2026?
Rapport Therapeutics reported that Abraham Ceesay sold 7,141 shares and 1,069 shares of common stock in two open-market transactions on September 8, 2026, for total reported sales of 8,210 shares.
At what prices did the RAPP CEO’s September 8, 2026 stock sales occur?
The reported prices are weighted averages. One sale of 7,141 shares had a weighted average price of $45.56, with individual trades between $44.94 and $45.90. The other sale of 1,069 shares had a weighted average price of $46.01, with trades between $45.95 and $46.17.
Were the RAPP CEO’s September 2026 stock sales under a Rule 10b5-1 trading plan?
Yes. The filing states that the reported transactions were effected by Abraham Ceesay under Rule 10b5-1 trading plans adopted on March 27, 2026, indicating the sales were pre-arranged.
Does the Form 4 show any remaining derivative securities for the RAPP CEO?
No. The filing’s derivative position summary shows no remaining derivative securities reported in this Form 4; only common stock transactions and holdings are listed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
